文献速递关节外科

地塞米松联合椎管内麻醉减少直接前入路非骨水泥全髋关节置换术后疼痛与阿片类药物用量的随机双盲安慰剂对照试验

A Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy of Dexamethasone Combined With Neuraxial Anesthesia in Reducing Pain and Opioid Consumption After Primary Cementless Total Hip Arthroplasty Using the Direct Anterior Approach.
PubMed 文献 · J Arthroplasty · 2025-06-12

90例在椎管内麻醉下经直接前入路行全髋关节置换术的患者随机接受单次静脉地塞米松10毫克或安慰剂(等渗盐水)。地塞米松组阿片类药物用量(吗啡毫克当量)显著低于安慰剂组(6.4±12.8 对 16.9±24.7,P=0.01),术后6小时和12小时视觉模拟评分较低,但1小时评分较高;活动度与计时起立行走测试无显著差异,未报告地塞米松相关并发症。

要点

  • 地塞米松组吗啡毫克当量显著低于安慰剂组(6.4±12.8 对 16.9±24.7,P=0.01)。
  • 术后6小时和12小时视觉模拟评分地塞米松组较低,但1小时评分较高。
  • 活动度与计时起立行走测试无显著差异,未报告地塞米松相关并发症。

核心结论

  • 术中地塞米松可能减少椎管内麻醉下全髋关节置换术的阿片类药物用量和早期术后疼痛,支持其在加速康复中的作用。
  • 尽管统计学显著性有限,但阿片类药物节省效应和良好安全性特征提示其可能用于多模式镇痛。
  • 需要进一步研究以优化剂量并确认临床获益。

研究设计与样本

  • 随机双盲安慰剂对照试验,共90例在椎管内麻醉下经直接前入路行全髋关节置换术的患者。
  • 患者随机接受单次静脉地塞米松10毫克或安慰剂(等渗盐水),两组围手术期麻醉方案相同。

主要发现

  • 地塞米松组吗啡毫克当量显著低于安慰剂组(6.4±12.8 对 16.9±24.7,P=0.01)。
  • 术后6小时视觉模拟评分地塞米松组低于安慰剂组(2.2±1.8 对 3.0±2.2,P=0.05)。
  • 术后12小时视觉模拟评分地塞米松组低于安慰剂组(2.7±2.0 对 3.7±2.4,P=0.03)。
  • 术后1小时视觉模拟评分地塞米松组高于安慰剂组(0.8±1.5 对 0.2±0.7,P=0.02)。
  • 活动度和计时起立行走测试结果无显著差异,未报告地塞米松相关并发症。

关键数值与推荐

  • 主要结局包括术后疼痛(视觉模拟评分)、阿片类药物用量(吗啡毫克当量)和24小时活动度。
  • 次要结局为计时起立行走测试和住院期间并发症。

临床怎么用

  • 术中地塞米松可能减少椎管内麻醉下全髋关节置换术的阿片类药物用量和早期术后疼痛,支持其在加速康复中的作用。
  • 阿片类药物节省效应和良好安全性特征提示其可能用于多模式镇痛。
  • 需要进一步研究以优化剂量并确认临床获益。

局限性

  • 需要进一步研究以优化剂量并确认临床获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-dose intravenous glucocorticoids are increasingly recognized for reducing postoperative pain, nausea, and opioid use in total hip arthroplasty (THA) and total knee arthroplasty. However, randomized studies assessing intraoperative dexamethasone versus placebo under neuraxial anesthesia (NA) are limited. METHODS: A total of 90 patients undergoing THA via the direct anterior approach under NA were randomized to receive either a single 10 milligrams intravenous dose of dexamethasone or placebo (isotonic saline). Demographics were similar between groups. Both groups followed identical perioperative anesthesia protocols. The primary outcomes included postoperative pain (visual analog scale), opioid use (morphine milligram equivalents), and range of motion at 24 hours. The secondary outcomes were the Timed Up and Go test and in-hospital complications. RESULTS: The MMEs were significantly reduced in the dexamethasone group compared to placebo (6.4 ± 12.8 versus 16.9 ± 24.7, P = 0.01). The visual analog scale scores were lower in the dexamethasone group at 6 and 12 hours postoperatively (2.2 ± 1.8 versus 3.0 ± 2.2, P = 0.05; 2.7 ± 2.0 versus 3.7 ± 2.4, P = 0.03), though the 1-hour score was higher in the dexamethasone group (0.8 ± 1.5 versus 0.2 ± 0.7, P = 0.02). There were no significant differences observed in range of motion or Timed Up and Go results. There were no complications related to dexamethasone reported. CONCLUSIONS: Intraoperative dexamethasone may reduce opioid use and early postoperative pain in THA under NA, supporting its role in enhanced recovery. While statistical significance was limited, the opioid-sparing effect and favorable safety profile suggest potential utility in multimodal analgesia. Further studies are needed to optimize dosing and confirm clinical benefits.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Schroven W, Verrewaere D, Deckmyn T, et al. A Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy of Dexamethasone Combined With Neuraxial Anesthesia in Reducing Pain and Opioid Consumption After Primary Cementless Total Hip Arthroplasty Using the Direct Anterior Approach. J Arthroplasty. 2025. PMID: 40516796. doi:10.1016/j.arth.2025.06.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。